Expertise in
5
conditions

Yvonne J. Summers

Manchester, ENG, GB 
Expertise in
5
conditions
Manchester, ENG, GB 

Overview

Yvonne Summers practices practicing medicine in Manchester, United Kingdom.

Ms. Summers is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

She is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Manchester, ENG, United Kingdom
Other Locations
St. Luke's Cancer Centre, Ashford And St. Peters' Hospitals, Oxford, ENG, United Kingdom
Wythenshawe, ENG M239LT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: AZD4547, Vistusertib, Palbociclib, Crizotinib, Selumetinib, Docetaxel, AZD5363, Osimertinib, Durvalumab, Sitravatinib, AZD6738
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
A Phase 1b/2, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)
A Phase 1b/2, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)
Enrollment Status: Unknown
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: RBN-2397
Study Phase: Phase 1/Phase 2
A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Enrollment Status: Unknown
Publish Date: February 25, 2020
Intervention Type: Drug
Study Drugs: AZD2014, Selumetinib
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

48 Total Publications

Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study.
Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study.
Journal: Clinical lung cancer
Published: April 07, 2026

Frequently Asked Questions about Yvonne J. Summers

Is Yvonne J. Summers a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Yvonne J. Summers is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yvonne J. Summers participate in research or clinical trials?

Yes. Yvonne J. Summers has published 48 articles and abstracts on conditions like Lung Cancer. You can view a list of Yvonne J. Summers's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Summers's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile